# Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

> **NCT00319787** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 102 (—)

## Conditions studied

- Locally Advanced Prostate Cancer

## Interventions

- **DRUG:** Iressa

## Key facts

- **NCT ID:** NCT00319787
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 102 (—)
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319787, "Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00319787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*